How GLP-1, PYY, and CCK Stop Eating
Satiety Peptides
3 Peptides, 1 Signal
GLP-1, PYY, and CCK are released simultaneously after meals from different gut cells, converging on brainstem and hypothalamic circuits to terminate eating.
Steinert et al., Physiological Reviews, 2017
Steinert et al., Physiological Reviews, 2017
View as imageNo single hormone stops you from eating. Three peptides released from your gut after a meal converge on the same brainstem circuits to create the feeling of fullness: GLP-1 (glucagon-like peptide-1), PYY (peptide YY), and CCK (cholecystokinin). Each one is released from different cells in response to different nutrients, operates through different receptors, and has a different time course. But they work together. Co-infusion of PYY and GLP-1 reduces energy intake by 27% at a buffet meal in healthy subjects, more than either hormone produces alone. For a deeper dive into CCK, the first satiety peptide discovered, see the pillar article.
Key Takeaways
- GLP-1 and PYY are co-secreted from intestinal L-cells within minutes of nutrient reaching the small intestine, while CCK is released from I-cells in the duodenum
- Lansbury et al. (2025) identified neurons in the right nodose ganglion that co-express receptors for all three peptides (GLP-1, CCK, and PYY), creating a single integration point for the combined satiety signal[1]
- Blanco et al. (2017) showed ghrelin actively suppresses secretion of all three satiety peptides, revealing a direct antagonism between the hunger and fullness systems[2]
- Lim et al. (2019) challenged the assumption that circulating satiety peptide levels drive meal termination, finding the dose-response relationship in pharmacological studies does not match physiological concentrations[3]
- Christiansen et al. (2018) demonstrated that short-chain fatty acids from gut bacteria stimulate GLP-1 and PYY secretion from the colon, linking the microbiome to appetite regulation[4]
- Luo et al. (2025) developed a dual CCK/GLP-1 receptor agonist that improved cognition in Alzheimer's mice, suggesting these satiety peptides have functions beyond appetite control[5]
Where Each Peptide Comes From
CCK: The Fast Responder
CCK was the first gut satiety peptide identified, discovered in 1928 as a factor that contracts the gallbladder. It is released from I-cells concentrated in the duodenum and upper jejunum within 15 minutes of eating, particularly in response to dietary fat and protein. CCK peaks quickly and has a short half-life (minutes), making it a meal-initiation signal rather than a sustained satiety factor.
CCK acts through two receptors. CCK-A receptors on vagal afferent nerves transmit satiety signals directly to the brainstem nucleus tractus solitarius (NTS). CCK-B receptors are found in the brain, but the vagal pathway is the primary route for meal-related satiety. This vagal mechanism explains why CCK's appetite-suppressing effect is substantially reduced by vagotomy.
GLP-1: The Incretin Satiety Signal
GLP-1 is released from L-cells throughout the small and large intestine in response to carbohydrates, fat, and protein reaching the gut lumen. It acts through the GLP-1 receptor (GLP-1R) expressed on vagal afferent neurons, brainstem neurons in the NTS and area postrema, and hypothalamic neurons. GLP-1's appetite effects combine direct brainstem activation with slowed gastric emptying, keeping food in the stomach longer and extending the feeling of fullness.
Native GLP-1 has a plasma half-life of only 2 to 3 minutes due to rapid degradation by the enzyme DPP-4. The pharmaceutical GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are engineered to resist DPP-4 and last hours to days, which is why their appetite suppression is so much more pronounced than what endogenous GLP-1 produces. For a comprehensive comparison, see every GLP-1 receptor agonist compared.
PYY: The Sustained Signal
PYY is co-secreted with GLP-1 from the same L-cells. It circulates primarily as PYY(3-36), which preferentially binds Y2 receptors in the hypothalamic arcuate nucleus. Y2 receptor activation inhibits NPY/AgRP neurons, the same orexigenic neurons that ghrelin activates. PYY levels rise during a meal and remain elevated for several hours afterward, providing a more sustained satiety signal than CCK.
PYY release is proportional to caloric load: larger meals produce more PYY and longer suppression of appetite. Fat is the most potent stimulus for PYY secretion, followed by protein, then carbohydrate. PYY has a longer half-life than either CCK or native GLP-1, which is why it maintains appetite suppression for hours after eating. This persistence makes PYY the primary hormonal signal for inter-meal satiety, the feeling that you do not need to eat again for a while, as opposed to CCK's role in terminating the current meal.
How They Converge: The Integration Points
Vagal Afferent Neurons
The vagus nerve is the primary highway connecting gut peptide signals to the brain. Lansbury et al. (2025) made a critical finding: neurons in the right nodose ganglion (the cell body cluster of the vagus nerve) co-express receptors for GLP-1, CCK, and PYY simultaneously.[1] This means individual vagal neurons can integrate all three satiety signals at once, rather than each peptide requiring its own dedicated neuron. The right nodose ganglion showed particularly high co-expression, suggesting lateralized processing of gut satiety information.
This co-expression provides a mechanism for synergy. When a single neuron receives CCK, GLP-1, and PYY signals simultaneously, the combined activation is greater than the sum of each signal alone. The neuron fires more intensely, sending a stronger satiety message to the brainstem.
The Brainstem NTS
Vagal afferents carrying the combined satiety signal terminate in the nucleus tractus solitarius (NTS), which functions as the first central relay station. The NTS integrates gut peptide signals with gastric stretch information (how physically full the stomach is) and blood glucose levels. From the NTS, the integrated signal projects to:
- The hypothalamic arcuate nucleus (where PYY directly inhibits hunger neurons)
- The paraventricular nucleus (which controls meal size)
- The parabrachial nucleus (which processes taste and palatability)
This convergence in the brainstem explains why satiety is experienced as a unified sensation rather than three separate signals. You feel "full," not "my CCK is up, my GLP-1 is elevated, and my PYY is climbing."
The NTS also receives direct GLP-1 input from neurons in the brainstem itself. A population of GLP-1-producing neurons in the NTS (distinct from the gut L-cells) synthesizes GLP-1 locally and projects to the hypothalamus and other appetite-regulating regions. This means GLP-1 signaling in the brain has both a peripheral gut-derived component (carried by the vagus) and a central brainstem-produced component, creating redundancy in the satiety system. The gut-derived peptides arrive first after a meal, and the central GLP-1 neurons may sustain or amplify the signal.
The Timing Cascade
The three peptides create a temporal sequence that spans an entire meal and its aftermath:
| Peptide | Release Trigger | Peak Time | Duration | Primary Target |
|---|---|---|---|---|
| CCK | Fat/protein in duodenum | 15 min | 30-60 min | Vagal CCK-A receptors |
| GLP-1 | Nutrients in small intestine | 30-60 min | 2-3 hrs (native) | Vagal GLP-1R, brainstem |
| PYY | Caloric load, especially fat | 60-90 min | 3-6 hrs | Hypothalamic Y2 receptors |
CCK fires first, slowing gastric emptying and initiating the satiety signal within minutes. GLP-1 rises next, amplifying the brainstem signal and further slowing the stomach. PYY peaks last and persists longest, maintaining appetite suppression well after the meal ends. This staggered release creates a satiety cascade rather than a single on/off switch.
Ghrelin: The Opponent Signal
The satiety peptides do not operate in isolation. Ghrelin, the hunger hormone, actively opposes them. Blanco et al. (2017) demonstrated that ghrelin directly suppresses secretion of CCK, PYY, and GLP-1 from the gut.[2] This is not just a passive relationship where ghrelin falls as satiety peptides rise. Ghrelin actively inhibits their release, creating a true antagonistic system.
Before a meal, ghrelin is high and satiety peptides are low. As food enters the gut, ghrelin drops and CCK, GLP-1, and PYY surge. The crossover point, where falling ghrelin meets rising satiety peptides, may represent the moment when eating behavior transitions from "seeking food" to "feeling satisfied."
Alyar et al. (2024) tracked ghrelin, GLP-1, and PYY in obese individuals undergoing diet and exercise interventions, finding that changes in these peptide levels correlated with appetite changes and weight loss outcomes.[6]
The Pharmacology vs. Physiology Problem
A critical question in satiety peptide research: do these hormones actually stop you from eating at the levels your body naturally produces? Lim et al. (2019) raised this challenge in a review titled "How Satiating Are the 'Satiety' Peptides."[3] Most studies demonstrating appetite suppression used pharmacological doses that produce blood levels well above what meals generate. At truly physiological concentrations, the individual contribution of any single peptide to meal termination may be modest.
Lim et al. (2023) followed up with a study finding no evidence that circulating GLP-1 or PYY levels were associated with increased satiety during a low-energy diet.[7] This does not mean these peptides are irrelevant to satiety, but it suggests that measuring blood levels alone misses the local paracrine and vagal mechanisms through which they may primarily operate. GLP-1, for instance, may exert its strongest satiety effects through local activation of vagal afferents in the gut mucosa before it even reaches the systemic circulation.
This pharmacology-versus-physiology gap explains why GLP-1 receptor agonists like semaglutide suppress appetite so dramatically: they bypass the short half-life and local action of native GLP-1, flooding the system with sustained, supraphysiological receptor activation. The success of these drugs does not prove that native GLP-1 is the dominant satiety signal; it proves that the GLP-1 receptor pathway can be pharmacologically exploited far beyond what the body naturally does with it.
This distinction matters for understanding obesity. If circulating satiety peptide levels do not strongly predict appetite in obese individuals, the problem may not be "too little satiety hormone" but rather altered sensitivity to these signals at the receptor or neural level, reduced local paracrine signaling that blood measurements miss, or changes in central processing of the satiety signal in the brainstem and hypothalamus.
The Microbiome Connection
The gut microbiome adds another layer. Christiansen et al. (2018) demonstrated that short-chain fatty acids (SCFAs), the fermentation products of dietary fiber by gut bacteria, directly stimulate GLP-1 and PYY secretion from colonic L-cells.[4] Acetate, propionate, and butyrate all triggered peptide release from isolated perfused rat colon, with butyrate showing the strongest effect.
This finding connects dietary fiber, the microbiome, and appetite into a single pathway. High-fiber diets feed gut bacteria that produce SCFAs, which stimulate L-cells to release GLP-1 and PYY, which suppress appetite. The satiety benefit of dietary fiber is at least partially mediated through peptide hormone release rather than just mechanical bulk in the stomach.
Wang et al. (2018) identified another nutrient-sensing mechanism: the calcium-sensing receptor (CaSR) expressed on gut enteroendocrine cells detects L-arginine in the intestinal lumen and stimulates secretion of GLP-1, PYY, and CCK simultaneously.[8] This receptor provides a direct molecular link between dietary protein sensing and the coordinated release of all three satiety peptides.
Beyond Appetite: Emerging Functions
These satiety peptides have roles beyond stopping eating. Luo et al. (2025) developed a novel dual CCK/GLP-1 receptor agonist and tested it in a mouse model of Alzheimer's disease (5xFAD mice).[5] The dual agonist ameliorated cognitive impairment, suggesting that combined activation of CCK and GLP-1 pathways in the brain has neuroprotective effects beyond appetite regulation. Keel et al. (2018) documented disturbances in gut satiety peptide profiles in patients with purging disorder, connecting these hormones to eating disorder pathophysiology.[9]
The Bottom Line
GLP-1, PYY, and CCK work as a coordinated satiety system rather than three independent hormones. CCK fires first from duodenal I-cells, GLP-1 and PYY follow from L-cells, and their signals converge on vagal neurons that co-express all three receptors. The brainstem integrates these signals with gastric stretch and blood glucose to produce the unified sensation of fullness. Ghrelin actively opposes this system by suppressing secretion of all three peptides. The pharmaceutical success of GLP-1 agonists exploits this biology by providing sustained supraphysiological activation of one arm of a three-peptide system.